{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:21:52Z","timestamp":1777486912395,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cisplatin (CDDP)-induced nephrotoxicity is a common dose-limiting toxicity, and diuretics are often administered to prevent nephrotoxicity. However, the efficacy and optimal administration of diuretics in preventing CDDP-induced nephrotoxicity remain to be established. This study aimed to evaluate the efficacy of combining furosemide and mannitol to prevent CDDP-induced nephrotoxicity. This was a post-hoc analysis of pooled data from a multicenter, retrospective, observational study, including 396 patients who received one or two diuretics for CDDP-based chemotherapy, compared using propensity score matching. Multivariate logistic regression analyses were used to identify risk factors for nephrotoxicity. There was no significant difference in the incidence of nephrotoxicity between the two groups (22.2% vs. 28.3%, P\u2009=\u20090.416). Hypertension, CDDP dose\u2009\u2265\u200975\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , and no magnesium supplementation were identified as risk factors for nephrotoxicity, whereas the use of diuretics was not found to be a risk factor. The combination of furosemide and mannitol showed no advantage over a single diuretic in preventing CDDP-induced nephrotoxicity. The renal function of patients receiving CDDP-based chemotherapy (\u2265\u200975\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) and that of those with hypertension should be carefully monitored. Magnesium supplementation is important for these patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-61245-6","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:01:45Z","timestamp":1715094105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity"],"prefix":"10.1038","volume":"14","author":[{"given":"Ayaka","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinako","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyouichi","family":"Tsumagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"61245_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 334, 115\u2013124 (2007).","journal-title":"Am. J. Med. Sci."},{"key":"61245_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73, 994\u20131007 (2008).","journal-title":"Kidney Int."},{"key":"61245_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","volume":"61","author":"V Launay-Vacher","year":"2008","unstructured":"Launay-Vacher, V. et al. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 61, 903\u2013909 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"61245_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1177\/1060028014533303","volume":"48","author":"KP Morgan","year":"2014","unstructured":"Morgan, K. P. et al. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann. Pharmacother. 48, 863\u2013869 (2014).","journal-title":"Ann. Pharmacother."},{"key":"61245_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jcpt.12509","volume":"42","author":"CM Mach","year":"2017","unstructured":"Mach, C. M. et al. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J. Clin. Pharm. Ther. 42, 286\u2013291 (2017).","journal-title":"J. Clin. Pharm. Ther."},{"key":"61245_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/jjco\/hyt122","volume":"43","author":"H Horinouchi","year":"2013","unstructured":"Horinouchi, H. et al. Short hydration in chemotherapy containing cisplatin (\u226575 mg\/m2) for patients with lung cancer: A prospective study. Jpn. J. Clin. Oncol. 43, 1105\u20131109 (2013).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"61245_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jjco\/hyt128","volume":"43","author":"K Hotta","year":"2013","unstructured":"Hotta, K. et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study in advanced lung cancer in the Okayama lung cancer study group Trial 1002. Jpn. J. Clin. Oncol. 43, 1115\u20131123 (2013).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"61245_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1007\/s10147-020-01755-1","volume":"25","author":"T Hase","year":"2020","unstructured":"Hase, T. et al. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: A prospective study. Int. J. Clin. Oncol. 25, 1928\u20131935 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"61245_CR9","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1007\/s00520-021-06790-w","volume":"30","author":"T Miyoshi","year":"2022","unstructured":"Miyoshi, T. et al. Preventive effect of 20 mEq and 8-mEq magnesium supplementation on cisplatin-induced nephrotoxicity: A propensity score-matched analysis. Support. Care Cancer 30, 3345\u20133351 (2022).","journal-title":"Support. Care Cancer"},{"key":"61245_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/jjco\/hyu004","volume":"44","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: A retrospective study. Jpn. J. Clin. Oncol. 44, 346\u2013354 (2014).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"61245_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00520-016-3426-5","volume":"25","author":"Y Saito","year":"2017","unstructured":"Saito, Y. et al. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support. Care Cancer 25, 481\u2013487 (2017).","journal-title":"Support. Care Cancer"},{"key":"61245_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona, D. J. et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22, 609\u2013619 (2017).","journal-title":"Oncologist"},{"key":"61245_CR13","first-page":"73","volume":"65","author":"S Ostrow","year":"1981","unstructured":"Ostrow, S. et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat. Rep. 65, 73\u201378 (1981).","journal-title":"Cancer Treat. Rep."},{"key":"61245_CR14","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00520-020-05703-7","volume":"29","author":"AM B\u00e9gin","year":"2021","unstructured":"B\u00e9gin, A. M. et al. Effect of mannitol on acute kidney injury induced by cisplatin. Support. Care Cancer 29, 2083\u20132091 (2021).","journal-title":"Support. Care Cancer"},{"key":"61245_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/1078155216656927","volume":"23","author":"RP Williams Jr","year":"2017","unstructured":"Williams, R. P. Jr., Ferlas, B. W., Morales, P. C. & Kurtzweil, A. J. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J. Oncol. Pharm. Pract. 23, 422\u2013428 (2017).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"61245_CR16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00520-015-2978-0","volume":"24","author":"T McKibbin","year":"2016","unstructured":"McKibbin, T. et al. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support. Care Cancer 24, 1789\u20131793 (2016).","journal-title":"Support. Care Cancer"},{"key":"61245_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1345\/aph.1Q333","volume":"46","author":"KP Morgan","year":"2012","unstructured":"Morgan, K. P., Buie, L. W. & Savage, S. W. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann. Pharmacother. 46, 276\u2013281 (2012).","journal-title":"Ann. Pharmacother."},{"key":"61245_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.1988.132","volume":"44","author":"G Daugaard","year":"1988","unstructured":"Daugaard, G. et al. Renal tubular function in patients treated with high-dose cisplatin. Clin. Pharmacol. Ther. 44, 164\u2013172 (1988).","journal-title":"Clin. Pharmacol. Ther."},{"key":"61245_CR19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/0360-3016(79)90677-1","volume":"5","author":"D Lehane","year":"1979","unstructured":"Lehane, D., Winston, A., Gray, R. & Daskal, Y. The effect of diuretic pre-treatment on clinical, morphological, and ultrastructural cis-platinum induced nephrotoxicity. Int. J. Radiat. Oncol. Biol. Phys. 5, 1393\u20131399 (1979).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"61245_CR20","first-page":"1269","volume":"39","author":"MF Pera Jr","year":"1979","unstructured":"Pera Jr, M. F., Zook, B. C. & Harder, H. C. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res. 39, 1269\u20131278 (1979).","journal-title":"Cancer Res."},{"key":"61245_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-003-0620-1","volume":"52","author":"JT Santoso","year":"2003","unstructured":"Santoso, J. T., Lucci, J. A., Coleman, R. L., Schafer, I. & Hannigan, E. V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother. Pharmacol. 52, 13\u201318 (2003).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"61245_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000510384","volume":"99","author":"T Miyoshi","year":"2021","unstructured":"Miyoshi, T. et al. Risk factors for cisplatin-induced nephrotoxicity: A multicenter retrospective study. Oncology 99, 105\u2013113 (2021).","journal-title":"Oncology"},{"key":"61245_CR23","first-page":"2490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490\u20132518 (2010).","journal-title":"Mechanisms of cisplatin nephrotoxicity. Toxins"},{"key":"61245_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","volume":"65","author":"NE Madias","year":"1978","unstructured":"Madias, N. E. & Harrington, J. T. Platinum nephrotoxicity. Am. J. Med. 65, 307\u2013314 (1978).","journal-title":"Am. J. Med."},{"key":"61245_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0b013e3282f88a1f","volume":"17","author":"GS Hill","year":"2008","unstructured":"Hill, G. S. Hypertensive nephrosclerosis. Curr. Opin. Nephrol. Hypertens. 17, 266\u2013270 (2008).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"61245_CR26","first-page":"S74","volume":"65","author":"LG Fine","year":"1998","unstructured":"Fine, L. G., Orphanides, C. & Norman, J. T. Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int. Suppl. 65, S74\u2013S78 (1998).","journal-title":"Kidney Int. Suppl."},{"key":"61245_CR27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1097\/01.hjh.0000181323.44162.01","volume":"23","author":"Y Ohta","year":"2005","unstructured":"Ohta, Y. et al. Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J. Hypertens. 23, 1905\u20131911 (2005).","journal-title":"J. Hypertens."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61245-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:07:24Z","timestamp":1715094444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61245-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61245"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61245-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3473918\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"21 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10511"}}